International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for …

CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present data on the company’s first-in-human clinical study in Parkinson’s disease at Neuroscience 2016. Session Information Type: NanosymposiumTitle: Transplants and Other Treatments of Parkinson’s DiseaseDate: November 14, 2016Time: 8:00 AM Location: SDCC 1B, San Diego Convention Center About the clinical studyThe Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranialy transplanted into patients with moderate to severe Parkinson’s disease (ClinicalTrials.gov Identifier: NCT02452723). The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson’s disease…


Link to Full Article: International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for …

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!